RxDoctor Payments Data

Shannon Klump, DO

Family Medicine · Comfort, TXNPI 1942360730

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 33 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$487
  • Abiomed$230
  • Novo Nordisk$136
  • Exact Sciences$36
  • Lilly USA, LLC$35
  • Pfizer$35
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$53752%
  • Education$48748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc5$487
Abiomed11$230
Novo Nordisk8$136
Exact Sciences2$36
Lilly USA, LLC2$35
Pfizer2$35
Bayer1$29
AbbVie1$23
GSK1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,024 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$149,444
Medicare patients
308
Services billed
1,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$64,320
EliquisApixaban33$39,343
MounjaroTirzepatide34$38,534
TrulicityDulaglutide24$33,849
RybelsusSemaglutide14$23,526
Breo ElliptaFluticasone/Vilanterol23$18,029
FarxigaDapagliflozin Propanediol14$14,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,837
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,876
TradjentaLinagliptin12$6,713
Gabapentin137$3,168
Esomeprazole Magnesium31$2,846
Rosuvastatin Calcium223$2,759
Levothyroxine Sodium286$2,648
Wixela InhubFluticasone Propion/Salmeterol11$2,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$136$87,84680 claims
Lilly USA, LLCMounjaro, Trulicity$35$72,38358 claims
PfizerEliquis$35$39,34333 claims
GSKBreo Ellipta$13$18,02923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Comfort

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →